CtrlK
MCK
NYSE
Health Care
$841.39
USD
+$0.08 (+0.01%)
At close: Jul 17, 2026, 4:00 PM EDT
Market Cap:
$99.69B
Volume:
1.1M
Previous Close
$841.31
Day Range
$839.91 - $861.00
52 Week Range
$637.00 - $999.00
Average Volume (10 Days)
950.0K
P/E Ratio (TTM)
20.93
Dividend Yield
0.38%
McKesson Corp. engages in providing healthcare services. The company is headquartered in Irving, Texas and currently employs 43,000 full-time employees. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. The company also offers oncology and specialty solutions.
CEO
Mr. Brian Tyler
Headquaters
Irving, TEXAS, US
Founded
1994
Employees
43,000
McKesson sold a 13% minority stake in its Medical-Surgical Solutions (MMS) division to Apollo Funds for $1.25 billion, valuing the unit at approximately $13 billion. The transaction is a key step toward McKesson's plan to spin off MMS as an independent public company in the second half of 2027. McKesson retains operating control and majority ownership of the division.
0
0
McKesson sold a 13% minority stake in its Medical-Surgical Solutions (MMS) division to Apollo Funds for $1.25 billion, valuing the unit at approximately $13 billion. The company retains operating control and majority ownership as it prepares to spin off MMS through an IPO in the second half of 2027. The deal marks a key milestone in McKesson's strategy to separate the lower-growth MMS business and focus on higher-margin specialty pharmaceutical opportunities.
0
0
McKesson sold a 13% minority stake in its Medical-Surgical Solutions (MMS) division to Apollo Funds for $1.25 billion, valuing the unit at approximately $13 billion. The transaction is a step toward McKesson's planned separation and public listing of MMS in the second half of 2027. McKesson retains operating control and majority ownership of the division.
0
0
